Immune responses to ISCOM formulations in animal and primate models.
about
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.Effect of adjuvants on the humoral immune response to congopain in mice and cattle.Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.Vaccines that facilitate antigen entry into dendritic cells.Lipid based particulate formulations for the delivery of antigen.ISCOM-based vaccines: the second decade.Nanoparticles as carriers for nasal vaccine delivery.Adjuvant effects of saponins on animal immune responsesThe role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Design and development of synthetic peptide vaccines: past, present and future.ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.Is intranasal vaccination a feasible solution for tuberculosis?Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.Vaccine adjuvants: smart components to boost the immune system.Immunomodulatory effect of tea saponin in immune T-cells and T-lymphoma cells via regulation of Th1, Th2 immune response and MAPK/ERK2 signaling pathway.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
P2860
Q31138173-AB6DF7A7-4726-4971-B989-0B1C7E73121AQ34279064-AF79885D-8B95-4322-91A6-0FF876F7CA68Q34447658-41C08D19-AA63-436B-BFA6-E45C463FE6ABQ35915763-2740E6BC-CF78-410C-8557-0B66A328C602Q36062119-9F775A87-F48A-4961-848A-E9B81AC2055DQ36062124-D6A9E37F-533E-4027-BA46-62364BC082C2Q36124952-40E783D2-4009-448E-A711-06C323D0CC98Q36745550-394A89D7-65D2-4D29-A937-9E308D46F6B5Q36758235-7B22B31B-863F-43F4-80CC-C17764C1FC18Q36899093-534D376B-A9CC-48BB-B2B5-5C9557474963Q36968280-CC334439-430A-4198-A200-4B355A9B142DQ36977750-4404C496-D9C9-4F04-9B82-5EB7BC232000Q37246405-F224E9E8-5278-4927-8E30-35DF7D7BC0F9Q37316013-EEE9BF65-92F6-4FF2-B6A6-4BA05091E0DAQ37452772-FD7FE83E-8135-4781-8ACD-37CCBFA00A2FQ50063256-498DAAAD-5215-40E5-BEB3-F7833E874AC1Q50457343-B43FF2FD-5D91-4AAB-88B4-99C9B79CF361Q52725104-5B268D47-2423-4E2B-A557-6828EBF05333
P2860
Immune responses to ISCOM formulations in animal and primate models.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Immune responses to ISCOM formulations in animal and primate models.
@ast
Immune responses to ISCOM formulations in animal and primate models.
@en
Immune responses to ISCOM formulations in animal and primate models.
@nl
type
label
Immune responses to ISCOM formulations in animal and primate models.
@ast
Immune responses to ISCOM formulations in animal and primate models.
@en
Immune responses to ISCOM formulations in animal and primate models.
@nl
prefLabel
Immune responses to ISCOM formulations in animal and primate models.
@ast
Immune responses to ISCOM formulations in animal and primate models.
@en
Immune responses to ISCOM formulations in animal and primate models.
@nl
P2093
P1433
P1476
Immune responses to ISCOM formulations in animal and primate models.
@en
P2093
P304
P356
10.1016/S0264-410X(00)00497-7
P407
P577
2001-03-01T00:00:00Z